BFRG Stock Overview
Through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Bullfrog AI Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.01 |
| 52 Week High | US$8.35 |
| 52 Week Low | US$1.43 |
| Beta | 0 |
| 11 Month Change | -11.06% |
| 3 Month Change | -21.48% |
| 1 Year Change | -34.10% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -57.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| BFRG | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | -11.5% | -8.3% | -1.0% |
| 1Y | -34.1% | 5.7% | 30.3% |
Return vs Industry: BFRG underperformed the US Healthcare Services industry which returned 5.7% over the past year.
Return vs Market: BFRG underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| BFRG volatility | |
|---|---|
| BFRG Average Weekly Movement | 12.6% |
| Healthcare Services Industry Average Movement | 8.1% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BFRG's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BFRG's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 6 | Vin Singh | www.bullfrogai.com |
Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease.
Bullfrog AI Holdings, Inc. Fundamentals Summary
| BFRG fundamental statistics | |
|---|---|
| Market cap | US$17.60m |
| Earnings (TTM) | -US$6.59m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.7x
P/E RatioIs BFRG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BFRG income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$6.59m |
| Earnings | -US$6.59m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.76 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 4.5% |
How did BFRG perform over the long term?
See historical performance and comparison